Top

Published in:

Open Access 01-11-2016 | Epidemiology

Young adult breast cancer patients have a poor prognosis independent of prognostic clinicopathological factors: a study from the Japanese Breast Cancer Registry

Authors: Akemi Kataoka, Takayuki Iwamoto, Eriko Tokunaga, Ai Tomotaki, Hiraku Kumamaru, Hiroaki Miyata, Naoki Niikura, Masaaki Kawai, Keisei Anan, Naoki Hayashi, Shinobu Masuda, Koichiro Tsugawa, Kenjiro Aogi, Takanori Ishida, Hideji Masuoka, Kotaro Iijima, Takayuki Kinoshita, Seigo Nakamura, Yutaka Tokuda

Published in: Breast Cancer Research and Treatment | Issue 1/2016

Abstract

Purpose

The aim of this study was to investigate whether young age at onset of breast cancer is an independent prognostic factor in patients from the Japanese Breast Cancer Registry, after adjustment of known clinicopathological prognostic factors.

Methods

Of the 53,670 patients registered between 2004 and 2006 and surveyed after a 5-year follow-up prognosis, 25,898 breast cancer patients (48.3 %), who were obtained prognostic data, were examined. Clinicopathological factors were compared between young adult (YA; <35 years), middle-aged adult (MA; 35–50 years), and older adult (OA; >50 years) patients. Five-year disease-free survival (DFS) and overall survival (OS) rates were studied.

Results

YA patients were associated with an advanced TNM stage and aggressive characteristics (e.g. human epidermal growth factor receptor 2 (HER2)-positive or oestrogen receptor (ER)-negative breast cancers) compared to MA and OA patients (P < 0.001). The 5-year DFS and OS rates were 79.4 % and 90.8, 88.5 and 95.0 %, and 87.8 % and 91.6 % for YA, MA, and OA patients, respectively. From the multivariable regression analysis, young age at onset was confirmed as an independent prognostic factor for both DFS (hazard ratio 1.73, 95 % confidence interval 1.42–2.10; P < 0.001) and OS (hazard ratio 1.58, 95 % confidence interval 1.16–2.15; P = 0.004).

Conclusions

Young age at onset is an independent negative prognostic factor in breast cancer. Further studies are required to develop new therapeutic strategies for YA breast cancer patients.

Available only for authorised users

Soliman H, Agresta SV (2008) Current issues in adolescent and young adult cancer survivorship. Cancer Control 15(1):55–62PubMed

Zebrack B (2008) Information and service needs for young adult cancer patients. Support Care Cancer 16(12):1353–1360. doi:10.1007/s00520-008-0435-z CrossRefPubMed

http://seer.cancer.gov/archive/csr/1975_2011/ [Accessed 19 April 2016]

Yankaskas BC (2005) Epidemiology of breast cancer in young women. Breast Dis 23:3–8CrossRefPubMed

Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63(1):11–30. doi:10.3322/caac.21166 CrossRefPubMed

Kataoka A, Tokunaga E, Masuda N, Shien T, Kawabata K, Miyashita M (2014) Clinicopathological features of young patients (<35 years of age) with breast cancer in a Japanese Breast Cancer Society supported study. Breast cancer 21(6):643–650. doi:10.1007/s12282-013-0466-2 CrossRefPubMed

Kroman N, Jensen MB, Wohlfahrt J, Mouridsen HT, Andersen PK, Melbye M (2000) Factors influencing the effect of age on prognosis in breast cancer: population based study. BMJ 320(7233):474–478CrossRefPubMedPubMedCentral

Nixon AJ, Neuberg D, Hayes DF, Gelman R, Connolly JL, Schnitt S, Abner A, Recht A, Vicini F, Harris JR (1994) Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Oncol 12(5):888–894PubMed

Gonzalez-Angulo AM, Broglio K, Kau SW, Eralp Y, Erlichman J, Valero V, Theriault R, Booser D, Buzdar AU, Hortobagyi GN, Arun B (2005) Women age ≤35 years with primary breast carcinoma: disease features at presentation. Cancer 103(12):2466–2472. doi:10.1002/cncr.21070 CrossRefPubMed

10.

Ahn SH, Son BH, Kim SW, Kim SI, Jeong J, Ko SS, Han W, Korean Breast Cancer S (2007) Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea–a report from the Korean Breast Cancer Society. J Clin Oncol 25(17):2360–2368. doi:10.1200/JCO.2006.10.3754 CrossRefPubMed

11.

Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, Zhang Y, Wang Y, Marcom PK, Marks JR, Febbo PG, Nevins JR, Potti A, Blackwell KL (2008) Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 26(20):3324–3330. doi:10.1200/JCO.2007.14.2471 CrossRefPubMed

12.

Partridge AH, Gelber S, Piccart-Gebhart MJ, Focant F, Scullion M, Holmes E, Winer EP, Gelber RD (2013) Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial. J Clin Oncol 31(21):2692–2698. doi:10.1200/JCO.2012.44.1956 CrossRefPubMed

13.

McGuire A, Brown JA, Malone C, McLaughlin R, Kerin MJ (2015) Effects of age on the detection and management of breast cancer. Cancers 7(2):908–929. doi:10.3390/cancers7020815 CrossRefPubMedPubMedCentral

14.

Kurebayashi J, Miyoshi Y, Ishikawa T, Saji S, Sugie T, Suzuki T, Takahashi S, Nozaki M, Yamashita H, Tokuda Y, Nakamura S (2015) Clinicopathological characteristics of breast cancer and trends in the management of breast cancer patients in Japan: based on the Breast Cancer Registry of the Japanese Breast Cancer Society between 2004 and 2011. Breast Cancer 22(3):235–244. doi:10.1007/s12282-015-0599-6 CrossRefPubMed

15.

Greene F (2002) TNM classification of malignant tumours, 6th edn. Wiley, New York, pp 131–141

16.

The Japanese Breast Cancer Society (ed) (2012) General rules for clinical and pathological recording of breast cancer, 17th edn. Kanehara Shuppan, Tokyo

17.

Lakhani S, Ellis I, Schnitt S, Tan P, van de Vijver M (2012) WHO classification of tumours of the breast, 4th edn. IARC Press, Lyon

18.

de la Rochefordiere A, Asselain B, Campana F, Scholl SM, Fenton J, Vilcoq JR, Durand JC, Pouillart P, Magdelenat H, Fourquet A (1993) Age as prognostic factor in premenopausal breast carcinoma. Lancet 341(8852):1039–1043CrossRefPubMed

19.

Albain KS, Allred DC, Clark GM (1994) Breast cancer outcome and predictors of outcome: are there age differentials? J Natl Cancer Inst Monogr 16:35–42PubMed

20.

Gnerlich JL, Deshpande AD, Jeffe DB, Sweet A, White N, Margenthaler JA (2009) Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease. J Am Coll Surg 208(3):341–347. doi:10.1016/j.jamcollsurg.2008.12.001 CrossRefPubMedPubMedCentral

21.

Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua MG, Pruneri G, Veronesi P, Torrisi R, Montagna E, Luini A, Intra M, Gentilini O, Ghisini R, Goldhirsch A, Colleoni M (2010) Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer. Ann Oncol 21(10):1974–1981. doi:10.1093/annonc/mdq072 CrossRefPubMed

22.

Han W, Kang SY, Korean Breast Cancer S (2010) Relationship between age at diagnosis and outcome of premenopausal breast cancer: age less than 35 years is a reasonable cut-off for defining young age-onset breast cancer. Breast Cancer Res Treat 119(1):193–200. doi:10.1007/s10549-009-0388-z CrossRefPubMed

23.

Azim HA Jr, Michiels S, Bedard PL, Singhal SK, Criscitiello C, Ignatiadis M, Haibe-Kains B, Piccart MJ, Sotiriou C, Loi S (2012) Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. Clin Cancer Res 18(5):1341–1351. doi:10.1158/1078-0432.CCR-11-2599 CrossRefPubMed

24.

Kollias J, Elston CW, Ellis IO, Robertson JF, Blamey RW (1997) Early-onset breast cancer–histopathological and prognostic considerations. Br J Cancer 75(9):1318–1323CrossRefPubMedPubMedCentral

25.

Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ, Panel m (2009) Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 20(8):1319–1329. doi:10.1093/annonc/mdp322 CrossRefPubMedPubMedCentral

26.

Ford D, Easton DF, Peto J (1995) Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 57(6):1457–1462PubMedPubMedCentral

27.

Honrado E, Benitez J, Palacios J (2005) The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications. Mod Pathol 18(10):1305–1320. doi:10.1038/modpathol.3800453 CrossRefPubMed

28.

Cancer Genome Atlas N (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61–70. doi:10.1038/nature11412 CrossRef

29.

Balmana J, Domchek SM, Tutt A, Garber JE (2011) Stumbling blocks on the path to personalized medicine in breast cancer: the case of PARP inhibitors for BRCA1/2-associated cancers. Cancer Discov 1(1):29–34. doi:10.1158/2159-8274.CD-11-0048 CrossRefPubMed

30.

Azim HA Jr, Partridge AH (2014) Biology of breast cancer in young women. Breast Cancer Res 16(4):427. doi:10.1186/s13058-014-0427-5 CrossRefPubMedPubMedCentral

31.

Aebi S, Gelber S, Castiglione-Gertsch M, Gelber RD, Collins J, Thurlimann B, Rudenstam CM, Lindtner J, Crivellari D, Cortes-Funes H, Simoncini E, Werner ID, Coates AS, Goldhirsch A (2000) Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet 355(9218):1869–1874CrossRefPubMed

32.

Voogd AC, Nielsen M, Peterse JL, Blichert-Toft M, Bartelink H, Overgaard M, van Tienhoven G, Andersen KW, Sylvester RJ, van Dongen JA, Danish Breast Cancer Cooperative Group. Breast Cancer Cooperative Group of the European Organization for R, Treatment of C (2001) Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. Journal of Clin Oncol 19(6):1688–1697

33.

de Bock GH, van der Hage JA, Putter H, Bonnema J, Bartelink H, van de Velde CJ (2006) Isolated loco-regional recurrence of breast cancer is more common in young patients and following breast conserving therapy: long-term results of European Organisation for Research and Treatment of Cancer studies. Eur J Cancer 42(3):351–356. doi:10.1016/j.ejca.2005.10.006 CrossRefPubMed

34.

Freedman RA, Virgo KS, Labadie J, He Y, Partridge AH, Keating NL (2012) Receipt of locoregional therapy among young women with breast cancer. Breast Cancer Res Treat 135(3):893–906. doi:10.1007/s10549-012-2156-8 CrossRefPubMed

35.

Ohuchi N, Suzuki A, Sobue T, Kawai M, Yamamoto S, Zheng YF, Shiono YN, Saito H, Kuriyama S, Tohno E, Endo T, Fukao A, Tsuji I, Yamaguchi T, Ohashi Y, Fukuda M, Ishida T, groups JSi (2016) Sensitivity and specificity of mammography and adjunctive ultrasonography to screen for breast cancer in the Japan strategic anti-cancer randomized trial (J-START): a randomised controlled trial. Lancet 387(10016):341–348. doi:10.1016/S0140-6736(15)00774-6 CrossRefPubMed

36.

Kinoshita T, Fukui N, Anan K, Iwamoto T, Niikura N, Kawai M, Hayashi N, Tsugawa K, Aogi K, Ishida T, Masuoka H, Masuda S, Iijima K, Nakamura S, Tokuda Y (2015) Comprehensive prognostic report of the Japanese Breast Cancer Society Registry in 2004. Breast Cancer. doi:10.1007/s12282-015-0644-5

37.

Anan K, Fukui N, Kinoshita T, Iwamoto T, Niikura N, Kawai M, Hayashi N, Tsugawa K, Aogi K, Ishida T, Masuoka H, Masuda S, Iijima K, Nakamura S, Tokuda Y (2015) Comprehensive prognostic report of the Japanese Breast Cancer Society Registry in 2005. Breast Cancer. doi:10.1007/s12282-015-0645-4

38.

Iwamoto T, Fukui N, Kinoshita T, Anan K, Niikura N, Kawai M, Hayashi N, Tsugawa K, Aogi K, Ishida T, Masuoka H, Masuda S, Iijima K, Nakamura S, Tokuda Y (2015) Comprehensive prognostic report of the Japanese Breast Cancer Society registry in 2006. Breast Cancer. doi:10.1007/s12282-015-0646-3

Title: Young adult breast cancer patients have a poor prognosis independent of prognostic clinicopathological factors: a study from the Japanese Breast Cancer Registry
Authors: Akemi Kataoka
Takayuki Iwamoto
Eriko Tokunaga
Ai Tomotaki
Hiraku Kumamaru
Hiroaki Miyata
Naoki Niikura
Masaaki Kawai
Keisei Anan
Naoki Hayashi
Shinobu Masuda
Koichiro Tsugawa
Kenjiro Aogi
Takanori Ishida
Hideji Masuoka
Kotaro Iijima
Takayuki Kinoshita
Seigo Nakamura
Yutaka Tokuda
Publication date: 01-11-2016
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2016
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-016-3984-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2016

The relationship between time to initiation of adjuvant chemotherapy and survival in breast cancer: a systematic review and meta-analysis

Evaluation of the effect of compression therapy using surgical gloves on nanoparticle albumin-bound paclitaxel-induced peripheral neuropathy: a phase II multicenter study by the Kamigata Breast Cancer Study Group

Use of a multiplexed immunoassay (PRO Onc assay) to detect HER2 abnormalities in circulating tumor cells of women with HER2-negative metastatic breast cancer: lack of response to HER2-targeted therapy

To be young, Black, and living with breast cancer: a systematic review of health-related quality of life in young Black breast cancer survivors

ANG1005 for breast cancer brain metastases: correlation between 18F-FLT–PET after first cycle and MRI in response assessment

Inhibition of 6-phosphofructo-2-kinase (PFKFB3) suppresses glucose metabolism and the growth of HER2+ breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer